# A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

> **NCT06637423** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (estimated)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Sacituzumab tirumotecan
- **DRUG:** Rescue medication
- **DRUG:** Supportive care measures

## Key facts

- **NCT ID:** NCT06637423
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-07-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06637423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06637423, "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06637423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*